Prognostic Value of Serum Exosomal AHCY Expression in Hepatitis B-Induced Liver Cirrhosis

Objective: We aimed to investigate serum exosomal adenosylhomocysteinase (AHCY) expression in hepatitis B-induced liver cirrhosis (HBV-LC) patients and to determine the prognostic value of serum exosomal AHCY. Methods: We collected serum samples from 100 patients with chronic hepatitis B (CHB) and from 114 HBV-LC patients to test serum exosomal AHCY expression using ELISA. Results: Compared with the CHB and Grade A and B HBV-LC groups, the level of exosomal AHCY expression was significantly higher in the HBV-LC group [376.62 (291.50–448.02) vs. 248.12 (189.28–324.63), P > 0.001] and the Grade C HBV-LC group [408.70 (365.63–465.76) vs. 279.76 (215.16–336.07), P > 0.001], respectively. Serum exosomal AHCY expression and MELD score had a significant positive correlation (r = 0.844, P < 0.001). Survival curve analysis showed that patients with low exosomal AHCY expression had significantly longer survival than patients with high exosomal AHCY expression (P = 0.0038). The receiver operating characteristics (ROC) curve showed that the area under the curve (AUC) value for the mortality prediction ability of serum exosomal AHCY in HBV-LC patients was 0.921, which was higher than the values for the MELD score (AUC 0.815) and Child-Pugh classification (AUC 0.832), with a sensitivity and specificity of 93.41 and 76.00%, respectively. Conclusions: The serum exosomal AHCY level is a novel potential prognostic biomarker in HBV-LC patients, which may be great significance for the prognosis of HBV-LC patients.

[1]  Yuanxiao Wang,et al.  The Potential of Serum Exosomal hsa_circ_0028861 as the Novel Diagnostic Biomarker of HBV-Derived Hepatocellular Cancer , 2021, Frontiers in Genetics.

[2]  Ming-jie Wang,et al.  Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection , 2021, Journal of hepatocellular carcinoma.

[3]  P. Vizán,et al.  Functional and Pathological Roles of AHCY , 2021, Frontiers in Cell and Developmental Biology.

[4]  Jian Wu,et al.  Plasma Exosome-Derived Sentrin SUMO-Specific Protease 1: A Prognostic Biomarker in Patients With Osteosarcoma , 2021, Frontiers in Oncology.

[5]  Linzhu Ren,et al.  Recent Progress on Exosomes in RNA Virus Infection , 2021, Viruses.

[6]  Hong Lu,et al.  Highly activated TRAIL+ CD56bright NK cells are associated with the liver damage in HBV-LC patients. , 2021, Immunology letters.

[7]  P. Kamath,et al.  Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. , 2020, Journal of hepatology.

[8]  K. Brzezinski.  S-adenosyl-l-homocysteine Hydrolase: A Structural Perspective on the Enzyme with Two Rossmann-Fold Domains , 2020, Biomolecules.

[9]  T. Tu,et al.  Hepatitis B Virus Infection: From Diagnostics to Treatments. , 2020, Viruses.

[10]  R. Shi,et al.  Mesenchymal Stem Cell-Derived Exosomes: Hope for Spinal Cord Injury Repair , 2020, Stem Cells and Development.

[11]  Jae Yeon Kim,et al.  Exosomes from Placenta-Derived Mesenchymal Stem Cells Are Involved in Liver Regeneration in Hepatic Failure Induced by Bile Duct Ligation , 2020, Stem cells international.

[12]  Cheng-Chia Yu,et al.  Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development , 2020, International journal of nanomedicine.

[13]  Li Yang,et al.  Roles of Macrophages and Exosomes in Liver Diseases , 2020, Frontiers in Medicine.

[14]  Lanjuan Li,et al.  Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study , 2020, Journal of viral hepatitis.

[15]  M. Ratajczak,et al.  Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future? , 2020, Leukemia.

[16]  M. Manns,et al.  Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta , 2020, Journal of viral hepatitis.

[17]  P. Rautou,et al.  EXTRACELLULAR VESICLES AS BIOMARKERS IN LIVER DISEASES: A CLINICIAN'S POINT OF VIEW. , 2020, Journal of hepatology.

[18]  K. Kharbanda,et al.  Role of Elevated Intracellular S-Adenosylhomocysteine in the Pathogenesis of Alcohol-Related Liver Disease , 2020, Cells.

[19]  S. Ahn,et al.  An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well‐controlled viremia , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[20]  Xieer Liang,et al.  Alanine aminotransferase influencing performances of routine available tests detecting hepatitis B‐related cirrhosis , 2020, Journal of viral hepatitis.

[21]  Mitchell R. McGill,et al.  Identification of Serum Biomarkers to Distinguish Hazardous and Benign Aminotransferase Elevations. , 2019, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  S. Gabrielsson,et al.  Personalized medicine and back–allogeneic exosomes for cancer immunotherapy , 2019, Journal of internal medicine.

[23]  Young Don Kim,et al.  Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. , 2018, Journal of hepatology.

[24]  H. Lee,et al.  High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B , 2017, Gut.

[25]  Junyan Han,et al.  Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer , 2017, PloS one.

[26]  Suh-Ching Yang,et al.  Impaired homocysteine metabolism in patients with alcoholic liver disease in Taiwan. , 2016, Alcohol.

[27]  Jonathan C. Cohen,et al.  Adult-onset liver disease and hepatocellular carcinoma in S-adenosylhomocysteine hydrolase deficiency. , 2015, Molecular genetics and metabolism.

[28]  Shuxia Han,et al.  MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma , 2014, World Journal of Surgical Oncology.

[29]  R. Horwitz.  From a clinician ' s point of view , 2019 .